Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Ceritinib bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Ceritinib is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Ceritinib?

Ceritinib (trade name Zykadia) is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer(NSCLC) following treatment with crizotinib.

More  information

CAS No.:1032900-25-6

Side Effect

The following side effects are common (occurring in greater than 30%) for patients taking ceritinib:

• Diarrhea
• Hemoglobin decreased
• Increase in liver enzymes
• Nausea
• Vomiting
• Increase in creatinine
• Abdominal pain
• Fatigue
• Glucose increased
• Decrease in phosphate
• Decreased appetite

These side effects are less common side effects (occurring in about 10-29%) of patients receiving ceritinib:

• Constipation
• Lipase increased
• Esophageal disorder (Heart burn, dyspepsia, dysphagia)
• Rash
• Bilirubin (total) increased

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.